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Introduction
China Liver Transplant Registry (CLTR) is the official 
national liver transplant (LT) registry in Mainland China 
that has been authorized by the National Health and Family 
Planning Commission of the People’s Republic of China 
(NHFPC) and serves for both regulatory and scientific 
purposes.
The CLTR 2011 annual scientific reports released 
national statistics showing current status of liver transplant 
(LT) in China. The analyses of the annual reports were 
performed by CLTR research center based on the data 
submitted by the transplant centers in mainland China, 
which is mandated by NHFPC. The annual reports had 
been reviewed by the scientific committee of CLTR (ScC) 
and approved by the NHFPC for formal release.
This article, as an accompanying document of CLTR 
2011 annual scientific report, provides an overview of 
scientific results for LT in China.
The overview
(I) A total number of 20,877 LT performed during 1980-
2011 in 81 certified transplant centers has been captured by 
CLTR, which grants CLTR the status of the third largest 
liver transplant database worldwide next to UNOS [113,432 
cases during 1988-2011 (1)] and Eurotransplant [100,542 
cases during 1968-2010 (2)];
(II) The number of LT per year steadily increased since 
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1993 with a peak of 2,970 cases in 2005 (Figure 1). Deceased 
donor liver transplantation (DDLT) accounted for the 
majority of LT (19,338, 92.63%) while living donor liver 
transplantation (LDLT) accounted for 7.37% (N=1,539) of 
LT;
(III) Results from the 2010 Global Observatory on 
Donation and Transplantation (GODT) report, produced 
by the WHO-ONT collaboration, indicated that among 
58 data reporting countries, China was ranked at second 
place next to the United States (6,291 cases) in terms of 
the number of LT in 2010 (Figure 2). Meanwhile, in all 
the 99 member countries/regions investigated, China was 
Figure 1 Number of Liver transplantation by Year. *From March 2010 to the end of 2011, there were 115 LT using grafts from China 
category donors
Figure 2 Liver transplantation by country in 2010 (3)
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among the 90 countries/regions which have had organ 
transplantation legislation in place (3);
(IV) The promulgation of the Regulation on Human 
Organ Transplantation in 2007 followed by a series of 
stringent polices led to a decline in the number of LT 
program. The number of current certified LT hospitals 
reduced to 81 by the year of 2009 and 70 (86.4%) of them 
located in the provincial capital. With the implementation 
of LDLT specific regulation policy of NHFPC in 2009, 
the number of LDLT decreased considerably, and the 
number of transplant centers practicing living donor organ 
transplantation dropped from 37 in 2009 to 17 in 2011;
(V) In March 2010, the pilot project of the new 
deceased organ donation was initiated. Meanwhile, the 
classification of decease organ donation in China, namely 
“China Category” was developed by the national organ 
transplantation committee (OTC) of NHFPC. The China 
Category is summarized as the following:
(i) China Category I (C-I): organ donation after brain 
death;
(ii) China Category II (C-II): organ donation after 
circulatory death;
(iii) China Category III (C-III): organ donation after 
brain death followed by circulatory death.
The classification was designed to be consistent with 
international classification standard for decease organ 
donation and respect the current cultural and societal value 
of Chinese people. From the initiation of the pilot program 
to the end of 2011, there were 115 LT (0.55% of all LT) 
performed using the liver grafts from China Categories 
donors. So far, 33 transplant centers from 19 provinces have 
started the LT in terms of China Categories;
(VI) An upward trend was observed in the number of 
LT from China Category donors since the initiation of the 
pilot program. There was a dramatic increase in number 
of China category donors by 186.67% in 2011 when 
comparing to that of the previous year. In addition, China 
Category donors represented 4.53% (86/1,897) of donor 
pool in 2011, which was close to the fraction of living 
donors (4.90%, 93/1,897) (Figure 1);
(VII) Central and south parts of China have the 
highest density in both the number of LT and the 
number of transplant centers. Among them, Shanghai 
(21.61%, 4,511/20,877), Beijing (19.84%, 4,142/20,877), 
Tianjin (17.85%, 3,727/20,877), Guangdong (11.05%, 
2,306/20,877) and Zhejiang (5%, 1,044/20,877) were the 
top five regions in term of the cumulative number of LT;
(VIII) In 2011, the LT rate was 1.41 per million 
populations in China. It was 20.92 PMP in Shanghai, 15.56 
PMP in Beijing, and 15.42 PMP in Tianjin, all of which 
presented a much higher rate than those in the rest of the 
country;
(IX) The cumulative number of pediatric LT was 540, 
accounting for 2.59% of total LT. There was a jump in the 
number of pediatric LTs from 39 in 2010 to 75 in 2011, 
an increase of 92.3%, probably due to the increase of the 
decease pediatric organ donors;
(X) Among adult recipients, the proportion of LT for 
HCC recipients was 43.63% (N=8,874). The proportion 
roughly remained unchanged over years (Figure 3). 64.9% 
HCC patients were beyond Milan criteria, probably due to 
a lack of consensus on HCC patient selection and national 
organ allocation system;
(XI) There were 289 liver-related multi-organ transplants 
performed nationwide, 82.70% of which (239/289) were 
liver-kidney transplantations. During the same period, 767 
cases of re-transplantation were documented in the registry. 
Meanwhile, 19 cases of dual-donor LT had been reported 
by 15 transplant centers since 2002;
(XII) The recipient post-transplant survival had been 
significantly improved over years (Figure 4). Comparing to 
2010, post-transplant complication rate in 2011 (49.13%) 
dropped more than 10% in both early and late post-
transplant period. Hospital mortality rate decreased to 
6.08% in 2011 from 36.79% in the years before 2000. 
There were improvements in graft survival rates over years. 
The unadjusted 1-year survival rate was 47.97% before 
2000 and it reached at 84.51% by 2010-2011.
Donors’ characteristics
(I) 95.74% of liver donors were male. However, the sex 
distribution showed different patterns across donor type 
(% of male donors: 98.32% among uncontrolled cardiac 
death donors, 82.58% among China Categories donors 
and 66.98% among living donors). In addition, there were 
changes in the sex-ratio in the group of living donors since 
2008. By 2011, the proportion of female living donors 
exceeded that of male living donors for the first time 
(51.65%/48.35%, female/male);
(II) The median age of donors was 29.84 years. It was 30 
for China Categories donors, 30.33 for living donors and 29 
for uncontrolled cardiac death donors;
(III) 30.35% of donated livers were from blood type 
O donors while 30.98% were from blood type A donors, 
and 28.60% and 10.06% were from blood type B and AB 
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donors. There were 370 (1.91%) cases of donor-recipient 
ABO blood type incompatible LT. Among them, A-O 
(donor-recipients) incompatible LT represented the largest 
fraction (29.19%, 108/370);
(IV) The majority of China Categories donors were C-II 
(DCD, 42.98%) and C-III (DBCD, 38.84%). Among the 
C-II group, 74.29% of them were Maastricht III donors. 
55.67% of causes of donor death were trauma and 18.29% 
were cerebral vascular accident.
Recipients’ characteristics
(I) 83.65% of LT recipients were male and the median age 
for all LT recipients was 48.5 years. The median age of 
LDLT recipients dropped gradually in the past four years, 
from 44.50 in 2008 to 23.90 in 2011;
(II) The pre-transplant diabetes mellitus was documented 
in 10.76% of recipients while pre-transplant hepatitis B 
infection was recorded in 76.64% of recipients;
(III) Cirrhosis (72.27%) was the leading pathological 
diagnosis for adult LT recipients (Table 1). HCC were found 
in 43.63% of adult LT recipients and the majority of whom 
(64.90%) were with tumor status beyond Milan criteria;
(IV) Biliary atresia (37.13%) and Wilson’s disease 
(23.23%) were two leading pathological and etiological 
diagnosis of pediatric recipients (Table 2);
(V) 0.86% of the recipients required ICU stay and 
respiratory support prior to transplant. 55.57% of the LT 
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Table 1 Diagnosis [pathology]
Diagnosis: pathology Adult, No. [%] Pediatric, No. [%]
Cirrhosis 14,685 [72.27] 168 [31.34]
Tumor [not associated with cirrhosis] 2,152 [10.59] 21 [3.92]
Graft failure 596 [2.93] 11 [2.05]
CAH 555 [2.73] 1 [0.19]
Fulminant hepatic failure 550 [2.71] 13 [2.43]
Chronic liver disease [CAH or cirrhosis] 497 [2.45] 0 [0]
Primary biliary cirrhosis 360 [1.77] 24 [4.48]
CAH acute flare 270 [1.33] 1 [0.19]
Cirrhosis with acute deterioration or complications 148 [0.73] 2 [0.37]
Polycystic disease 76 [0.37] 1 [0.19]
Secondary biliary cirrhosis 63 [0.31] 3 [0.56]
Primary sclerosing cholangitis 51 [0.25] 2 [0.37]
Budd-Chiari syndrome 45 [0.22] 3 [0.56]
Other metabolic disease 43 [0.21] 38 [7.09]
Biliary atresia 14 [0.07] 199 [37.31]
Familial amyloidotic polyneuropathy 5 [0.02] 1 [0.19]
Unspecified 210 [1.03] 48 [8.96]
Total 20,320* [100] 536* [100]
*Excluded cases (Adult: missing N=17; Pediatric: missing N=4) with missing pathological diagnosis
Table 2 Diagnosis [etiology]
Diagnosis: etiology Adult, No. [%] Pediatric, No. [%]
HBV 15,834 [78.32] 30 [5.91]
HCV 1,313 [6.49] 0 [0]
Idiopathic/cryptogenic 718 [3.55] 50 [9.84]
ETOH 561 [2.77] 0 [0]
Auto-immune 475 [2.35] 12 [2.36]
Non-A to C 267 [1.32] 13 [2.56]
Wilson’s Disease 140 [0.69] 118 [23.23]
Drug induced 77 [0.38] 6 [1.18]
Technical 74 [0.37] 0 [0]
Congenital 72 [0.36] 227 [44.69]
HAV 22 [0.11] 0 [0]
Unspecified 664 [3.28] 52 [10.24]
Total 20,217* [100] 508* [100]
*Excluded cases (Adult: missing N=120; Pediatric: missing 
N=32) with missing etiological diagnosis
recipients had been admitted to the general ward due to 
liver disease related complications and 40.88% of them 
stayed in their home while waiting for LT (Figure 5);
(VI) The median MELD score at the time of transplant 
dropped gradually in the recent years (Figure 6). But the 
median PELD score at the time of transplant increased 
steadily in the recent years (Figure 7). The national liver 
and kidney allocation policy of People’s Republic of China 
promulgated by the NHFPC in Dec. 2010 adopted MELD/
PELD-based ranking system for allocation of deceased 
donor livers. Prior to this, no consensus has been reached 
with respect to the allocation rules at the national level so 
that the extent to which the MELD/PELD was applied as 
the ranking criteria for LT varied among centers.
Recipients’ intra-operative data
(I) The median anhepatic phase time ranged between 55 to 
60 minutes in the past 9 years. LT from China Categories 
donors achieved the shortest anhepatic phase (51.50 minutes 
in median) among three groups of donors (57 minutes for 
LT from uncontrolled cardiac death donors and 70 minutes 
for LT from living donors);
(II) The median cold ischemia time for all LT was 
8 hours. It was 6.19 hours for LT from China Categories 
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Figure 5 Recipients’ status prior to transplant
Figure 6 Median MELD score at the time of transplant
Figure 7 Median PELD score at the time of transplant
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donors, which was shorter than those from uncontrolled 
cardiac death donors (8.17 hours);
(III) Biliary stent was used in 38.56% of total LT. There 
was a decreased trend on the usage of biliary stent over 
years (25.36% in 2011);
(IV) The median volume of blood loss in LT was 
2,000 mL, 66.10% of which were less than 3,000 mL;
(V) The median operation time of all LT was 8 hours. 
It was 7.5 hours in 2011, the first time less than 8 hours. 
For China Categories donors, it was 7 hours in 2010 and 
6.5 hours in 2011, both of which were less than that from 
uncontrolled cardiac donors during the same period;
(VI) The overall rate of intra-operative complications 
was 12.22%, among which intra-operative blood loss 
(8.57%) was ranked on the top. The overall intra-operative 
complications rate had decreased from 17.73% in 2010 to 
11.70% in 2011;
(VII)  The immunosuppressant  regimen of  the 
combination of Tacrolimus and mycophenolate mofetil 
were used in 70.85% of LT recipients. Steroids were used in 
87.85% of the recipients in conjunction with this regimen.
Post-transplant outcome
(I) The early (<30 days) post-operative complications 
were observed in 68.51% of the patients receiving LT. 
Among which, pleural effusion (47.05%), diabetes 
mellitus (32.06%), peritoneal effusion/abscess (32.02%), 
and post-transplant infections (30.35%) were the 
leading complications. The rate of early post-transplant 
complications was 49.13% in 2011, the lowest level over the 
years (Figure 8);
(II) The late postoperative complication occurred 
in 32.76% of the patients receiving LT during the 
reported time period. Diabetes mellitus (16.55%), biliary 
complications (8.74%), and hypertension (8.41%) were the 
leading types (Figure 8);
(III) The hospital mortality rate significantly decreased 
over the decade. This was confirmed by a downward trend 
from 26.26% in 2000 to 6.08% in 2011. Nevertheless, it 
was reported that 58.69% of the patients suffering from 
post-transplant renal failure died before discharge. The 
hospital mortality rate was lower in adult transplant (7.82%) 
than in pediatric transplants (9.07%), but with no statistical 
significance. Differences in hospital mortality rate were also 
observed across donor types. In 2011, patients receiving 
LT from China category donors were observed highest 
hospital mortality rate (7.06%) compared to the other two 
donor types. (6.45% for LDLT and 6.01% for LT from 
uncontrolled cardiac death donors);
(IV) The 1-year, 3-year, and 5-year cumulative rate 
of biliary complications were 11.41%, 15.41%, and 
17.73%, respectively. There was significant difference 
(P<0.001) across donor types. The cumulative rates of 
biliary complications was the highest in cadaver split LTs, 
which was 19.37%, 30.81%, 30.81% at 1, 3 and 5 years, 
respectively;
(V) The 1-year, 3-year and 5-year cumulative rate of 
post-transplant heptocellular carcinoma recurrence was 
19.28%, 29.53%, and 33.69%, respectively;
Figure 8 Accumulative incidence of post-operative complications
86.87%
81.93%
76.51%
69.84%
71.75%
67.30% 69.93%
77.86%
70.03%
74.52%
67.93%
60.26%
49.13%
51.40%
47.49%
50.00%
40.54%
43.13%
37.31%
33.87%
38.96%
32.30%
32.65%
33.02%
24.23%
12.49%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
<2000 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Incidence
Transplant year
Early post-operative complication % of total
Late post-operative complication % of total
195HepatoBiliary Surgery and Nutrition, Vol 2, No 4 August 2013
© Hepatobiliary Surgery and Nutrition. All rights reserved. Hepatobiliary Surg Nutr 2013;2(4):188-197www.thehbsn.org
(VI) The 1-year, 3-year and 5-year cumulative post-
transplant rate of recurrence for hepatitis B was 1.67%, 
3.18%, 4.23%, respectively.
Survival analysis
(I) The median post-transplant follow-up was 14.74 months, 
of which the longest was 192.47 months. 5.01% of 
recipients were lost to follow up;
(II) The 1-year, 3-year and 5-year cumulative survival 
rate for all recipients was 77.97%, 65.38% and 60.53%, 
respectively (Figure 9);
(III) The 1-year, 3-year, and 5-year survival rate was 
76.49%, 63.6%, and 58.42%, for adult recipients and 
78.13%, 65.81%, and 59.25% for pediatric recipients;
(IV) Both LT from China Categories donors (1-year: 
82.77%; 3-year: 69.67%; 5-years: 58.06%) and from living 
donors (1-year: 82.53%; 3-year: 72.05%; 5-year: 68.55%) 
yield higher unadjusted graft survival than LT from 
uncontrolled cardiac death donors (1-year: 76.01%; 3-year: 
62.95%; 5-year: 57.65%) (P<0.001);
(V) Up to 2011, there were 958 adult LT for acute liver 
failure/fulminate hepatic failure patients, with 1-year, 3-year, 
and 5-year graft survival rate of 67.79%, 60.54%, and 
59.40%, respectively;
(VI) There were significant difference in graft survival 
rates of different age groups (P<0.001). Those of aged 
60 years and older (2,610 recipients) had the lowest graft 
survival at 1-year (71.93%), 3-year (60.18%), and 5-year 
(55.94%) post-transplant among all adult recipients 
(Figure 10).
(VII) The graft survival rates of pediatric recipients 
had no significant difference among different age groups 
(P=0.134). There were total 132 recipients aged less than 
1 year, of which 1-year, 3-year, and 5-year survival rate was 
68.55%, 49.11%, and 49.11%, respectively (Figure 11).
Independent risk factors for survival were analyzed via 
univariate survival analysis and were summarized in the 
Appendix III of the CLTR 2011 annual scientific report. 
The analysis is to be updated every three years and will be 
reported in a separate publication.
Conclusions
The CLTR 2011 annual scientific report releases national 
statistics and scientific findings regarding LT in Mainland 
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Figure 10 Unadjusted graft survival by age group among adult recipients. *Excluded cases (missing N=136) without the complete follow up 
or survival status report
Figure 11 Unadjusted graft survival by age group among pediatric recipients. *Excluded cases (missing N=3) without the complete follow 
up or survival status report 
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China during 1980-2011. This article, written as an 
accompanying document to the annual report, provides a 
brief summary of the scientific results along with updated 
information of the current LT activities in China. It is 
designed to meet the needs of readers from a wide range 
of fields, including health authorities, experts and scholars 
in transplant communities, officer of community service, 
as well as transplant patients and their families. Issues 
covered in the previous annual reports mainly focus on 
transplantation trend, transplant centers statistics, and 
recipients’ demographical pattern and post-transplant 
outcome. The 2011 report also briefed the readers on 
the current changes to the decease liver allocation and 
introduced the principles applied in the national deceased 
liver and kidney allocation policy of 2010. With the 
implementation of national liver allocation policy and 
national organ allocation computing system, we expect that 
the waitlist and the allocation statistics will be available to 
the public in the coming years. In addition to construction 
of the national allocation system, the data from China 
category donors is another new topic brought to this year’s 
report. The increase in the number of LT from the organ 
over years as well as the rapid expansion of the new national 
deceased organ donation program confirmed its values and 
feasibility in China. Conducted under the Human Organ 
Transplantation Regulation and governed by the health 
authorities, the new deceased organ donation program is 
expected to become the main organ source in Mainland 
China in the coming years.
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